Seaport Therapeutics, a clinical-stage biopharmaceuticcal company that is charting a proven path in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round. The round was co-led by ARCH Venture Partners and Sofinnova Investments along with Third Rock Ventures and Seaport founder PureTech Health..

Seaport Therapeutics是一家临床阶段的生物制药公司，正在为神经精神病学绘制一条行之有效的道路，该公司宣布结束一轮1亿美元超额认购的a系列融资。这一轮由ARCH Venture Partners和Sofinnova Investments以及Third Rock Ventures和Seaport创始人PureTech Health共同领导。。